Pharmaceutical Technology

MARCH 24, 2023

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Many pharma companies hold extensive patent protections and have ongoing patent litigation cases. For example, the cost of Humira biosimilars in Denmark decreased by 82% from September 2018 to December 2018.

Competition 59

Competition Marketing FDA Physicians 59

pharmaphorum

JULY 27, 2022

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

Government 98

Government Recruitment Medicine Patients 98

Pharmaceutical Technology

JANUARY 22, 2023

In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. This was not always the case. “Up A major symptom of MCT8 deficiency is an overexpression of T3.

FDA 126

FDA Safety Pharmaceutical Patients 126

pharmaphorum

JANUARY 25, 2023

To ensure an optimised engagement model critical to long-term success in today’s highly competitive commercial market, life sciences companies need to effectively leverage AI-powered technology. Organisations need to develop an integrated end-to-end commercial strategy to fuel data-driven insights and guide decision-making.

Marketing 98

Marketing Sales Retail Management 98

Pharmaceutical Technology

DECEMBER 4, 2022

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Humira biosimilars became available in the EU in October 2018. There are seven FDA-approved Humira biosimilars, of which Amgen’s Amjevita will be launched in January.

Marketing 104

Marketing Physicians Competition Patients 104

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

pharmaphorum

JANUARY 4, 2023

Despite the introduction of the GDPR 3 in 2018, studies have demonstrated that the legislation has, unfortunately, been unevenly implemented and interpreted throughout by Member States. It has been proposed that the amount of these fees charged by the data holder must be transparent, proportionate, and “must not restrict competition” 10.

Pharmaceutical 98

Pharmaceutical Electronics Healthcare Healthcare 98

Clarivate

APRIL 24, 2023

Pharmacy giants battle to bulk up with provider group buys CVS Health rattled the healthcare industry when it acquired one of the nation’s top insurers, Aetna, in 2018, and the giant retailer continues to make waves. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Pharmaceutical Technology

JUNE 2, 2023

With such a tight grip on the market, AbbVie has come under heavy criticism for repeated price hikes on Humira and avoiding competition from biosimilar manufacturers with an aggressive patent strategy. Its unclear how well Cost Plus Drugs will fare against traditional pharma. But now the race has begun across the Atlantic.

Marketing 52

Marketing Competition Insurance Prospecting 52

Pharmaceutical Technology

MARCH 15, 2023

According to GlobalData’s Pharma Intelligence Center Deals Database, figure 1 shows the parent holding company SVB Financial Group and its subsidiaries were involved in more than $1.4bn in total venture financing raised from 2010 to 2022 for drug development. in deposits.

Medicine 59

Medicine Marketing Pharma Government 59

Pharmaceutical Technology

JUNE 22, 2023

Data exclusivity has been a heated point of debate in the recently announced pharmaceutical reform, which aims to shorten it from eight years to six, drawing the ire of pharma companies. As per the EC’s proposed pharma reform, only 10 vouchers will be given during this 15-year period.

Pharma 52

Pharma Pharmaceutical Government Marketing 52

World of DTC Marketing

JANUARY 31, 2021

SUMMARY: “How big pharma takeovers destroy innovation” a report from Congresswoman Porter does make some points. I always have pointed instances in which pharma puts Wall Street first and patients second. I have worked with and stayed in contact with some R&D people within pharma and they have a different answer.

Pharma 187

Pharma Insurance Pharmaceutical Healthcare 187

World of DTC Marketing

JULY 27, 2022

Pharma companies have very little control over patients’ prices for their Rxs. In 2021 pharma provided a staggering $204 billion in price concessions for brand-name medicines to PBMs. Those health insurers, in turn, use the discounts to offer more competitive premiums in a bid to attract enrollees.

Insurance 226

Insurance Prescription Medicine Medical 226

World of DTC Marketing

JULY 9, 2021

We are reminded that big pharma is a business whose only purpose is to make money. Pharma loves to use the argument that they need high prices and new products for R&D. One company, Amgen, spent nearly six times as much on buybacks, dividends, and executive compensation as it did on R&D in 2018. That is reprehensible.

Pharma 292

Pharma FDA Leads Competition 292

Clarivate

MAY 31, 2023

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52

Pharma Biopharma Medicine Healthcare 52

Impetus Digital

MARCH 15, 2024

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). There are currently more than 2,000 oncology products under development.

Recruitment 78

Recruitment Patients Healthcare Provider Healthcare 78

Pharmaceutical Technology

MARCH 24, 2023

Results from the Phase II trial were released for the vaccine in September 2018. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Pharma 64

Pharma Side effects Marketing Biopharma 64

pharmaphorum

JULY 12, 2022

The deal centres on La Jolla’s lead product Giapreza (angiotensin II), used to increase blood pressure in adults with septic shock, and antibiotic Xerava (eravacycline) for complicated intra-abdominal infections (cIAIs), approved by the FDA in 2017 and 2018, respectively.

Pharma 52

Pharma Sales Marketing Competition 52

Pharmaceutical Technology

JANUARY 10, 2023

Last August, CinCor Pharma raised $258.7 Between 2018 and 2022 the drug company prioritised cardiovascular deals with completing six deals totaling $40 billion in value, as per GlobalData. million dollars in a public offering of common stock and pre-funded warrants , and. A shift towards cardiovascular disease.

Prospecting 98

Prospecting Pharma Pharmaceutical Competition 98

Healthcare Success

MAY 9, 2022

Ready to start leveraging QR code technology and stay ahead of your competition? The Resurgence of QR Codes in Health & Pharma. According to Statista, 11 million households scanned a QR code in 2020—over 2 million more than in 2018—and that number continues to rise. They were solving a problem that didn’t exist—yet.

Leads 109

Leads Patients Healthcare Provider Healthcare 109

Pharma Marketing Network

JUNE 8, 2020

RJ (PMN): Hi this is RJ Lewis, your host of the pharma marketing network podcast and I’m excited today to have with me a couple of executives from Klick Health to talk about CCPA. RJ (PMN): Why does this impact health and pharma more than other industries like automotive, or beauty products etc. Welcome to the podcast!

Marketing 40

Marketing Pharma Healthcare Healthcare 40

Pharmaceutical Technology

SEPTEMBER 26, 2022

Both Sandoz and Novartis are internationally renowned pharma companies, with a combined 34 production facilities worldwide. Strong competition limits Sandoz's growth. On 27 March 2018, GlaxoSmithKline (GSK) (Brentford, UK) announced that it had reached an agreement with Novartis for the buyout of Novartis’ 36.5%

Competition 64

Competition Manufacturing Marketing Distribution 64

pharmaphorum

AUGUST 5, 2022

And, for M&A deals valued at more than $500M, the average takeout premium in biopharma has grown from 51% in 2018, to roughly 71% in 2021. Collaboration across the industry is needed now more than ever before across this complex ecosystem – not least because it’s becoming a competitive landscape. About the Author. References. [1]

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Healthcare Success

MAY 9, 2022

Ready to start leveraging QR code technology and stay ahead of your competition? The Resurgence of QR Codes in Health & Pharma. According to Statista, 11 million households scanned a QR code in 2020—over 2 million more than in 2018—and that number continues to rise. They were solving a problem that didn't exist—yet.

Leads 52

Leads Patients Healthcare Provider Healthcare 52

World of DTC Marketing

FEBRUARY 23, 2021

SUMMARY: Pharma’s reputation got a bump the latest Harris Poll survey shows but behind the numbers is more of a reality. Overall, about 16% of Americans had a negative or more negative view of pharma in mid-May, which was again on par with April sentiment. The COVID vaccines will make billions for pharma and some senior executives.

Pharma 164

Pharma Side effects Media Insurance 164

Clarivate

OCTOBER 17, 2024

As California Attorney General from 2011 to 2017, Harris was a forceful opponent of healthcare industry consolidation, both vertical and horizontal, believing that mergers of hospitals, physician groups and insurers would damage competition and raise prices for care.

Healthcare 52

Healthcare Healthcare Government Insurance 52